What muvalaplin is
Muvalaplin is an oral small-molecule drug developed by Eli Lilly that inhibits the formation of lipoprotein(a), or Lp(a). Most Lp(a) drugs in development, such as pelacarsen, olpasiran, and lepodisiran, are injectable nucleic-acid drugs that stop the liver from making apolipoprotein(a). Muvalaplin works differently: it interferes with apolipoprotein(a) assembling with the lipoprotein particle to form Lp(a). It is taken once a day by mouth.
Why the target matters
Lp(a) is a largely inherited cardiovascular risk factor. A 2009 study in JAMA found that people with genetically elevated Lp(a) had a higher risk of heart attack, which supports a causal role and the case for lowering it. There is no approved drug that specifically lowers Lp(a).
Clinical evidence
Phase 1
According to the Phase 2 publication, a 14-day Phase 1 study found muvalaplin was well tolerated and reduced Lp(a) by up to 65%.
Phase 2: KRAKEN
KRAKEN was a 12-week, placebo-controlled trial in 233 adults at high cardiovascular risk with elevated Lp(a), published in JAMA in 2025.
| Daily dose | Placebo-adjusted Lp(a) change (intact Lp(a) assay) | Placebo-adjusted Lp(a) change (apolipoprotein(a)-based assay) |
|---|---|---|
| 10 mg | −47.6% | −40.4% |
| 60 mg | −81.7% | −70.0% |
| 240 mg | −85.8% | −68.9% |
Source: Nicholls et al., JAMA (2025).
Apolipoprotein B fell by 8.9% to 16.1%, and there was no change in high-sensitivity C-reactive protein, a marker of inflammation. The investigators observed no safety or tolerability concerns at any dose.
Phase 3: MOVE-Lp(a)
MOVE-Lp(a) compares muvalaplin with placebo for preventing major cardiovascular events in adults with elevated Lp(a). ClinicalTrials.gov lists an estimated 10,450 participants, recruitment beginning in September 2025, and an estimated primary completion in March 2031.
Scientific perspective
Why two assays give two answers
KRAKEN reported two sets of results because standard Lp(a) tests measure apolipoprotein(a). A drug that blocks apolipoprotein(a) from joining the particle could leave free apolipoprotein(a) in the blood, which a standard test would still count. An intact-particle assay measures only assembled Lp(a). The roughly 15-point gap between the two methods at higher doses is a reminder that a lab measurement is not the same as a clinical effect. See What Is a Primary Clinical Trial Endpoint?
After Lp(a)HORIZON
Pelacarsen's 2026 outcomes trial showed that lowering Lp(a) by about 78% did not reduce cardiovascular events in that population. Muvalaplin's reductions are of a broadly similar order on the standard assay. Whether a different mechanism, daily oral dosing, or a different trial design changes the outcome is unknown. MOVE-Lp(a) is the trial that will answer it, years from now.
Development perspective
- Regulatory status: muvalaplin has no FDA approval.
- Timing: MOVE-Lp(a) is the latest of the major Lp(a) outcomes trials to report, with an estimated primary completion in 2031. By then, the results of injectable Lp(a) drugs' outcomes trials should largely determine expectations for the class.
- Practical appeal: if the class succeeds, a daily pill could be easier to prescribe and start than an injection, although adherence to daily dosing is a known challenge for long-term preventive drugs.
- Historical benchmark: about 52% of programs that have reached Phase 3 have eventually been approved. This average does not account for the 2026 pelacarsen result.
Competitive context
Muvalaplin is Lilly's second Lp(a) drug, alongside the injectable siRNA lepodisiran. It is the only oral Lp(a)-lowering drug among the agents profiled on this site.
Development timeline
- Nov 24, 2022KRAKEN Phase 2 trial begins. Registry
- Jan 21, 2025KRAKEN results published: placebo-adjusted Lp(a) reductions of up to 85.8% (intact assay) and about 70% (apolipoprotein(a)-based assay). Peer-reviewed
- Sep 2, 2025MOVE-Lp(a) Phase 3 cardiovascular outcomes trial begins. Registry
- Sep 4, 2026Read-across: pelacarsen, an injectable Lp(a)-lowering drug, misses the primary endpoint of its Phase 3 outcomes trial. Company-reported
What could change the outlook
- Progress of MOVE-Lp(a), including any registry amendments to size, endpoint, or timing after the pelacarsen result.
- Earlier Lp(a) outcomes trial results (olpasiran, then lepodisiran), which will shape expectations for the whole class before MOVE-Lp(a) reads out.
- Long-term safety data. A daily pill taken for years requires a different safety record than an infrequent injection.
- Clarification of which Lp(a) assay best reflects the drug's true effect, given the gap between measurement methods in Phase 2.